FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash
Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…
